Sep 28, 2023
Fractyl Health to Present Pioneering Data on Revita® and Rejuva® Programs at the European Association for the Study of Diabetes (EASD) 2023 Scientific Congress
...
Sep 14, 2023
Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer
Aug 30, 2023
Fractyl Health Mourns the Passing of Esteemed Board Member Brian Dovey
Aug 1, 2023
Fractyl Health Announces Clinical Update on Revita Real World Registry in Germany and Launch of Revita+ Telehealth Program Combining Behavioral Recommendations with Revita Treatment for Type 2 Diabetes
Fractyl Health gibt aktuelle Informationen zur Revita® Real World Register Studie in Deutschland und zur Initiierung des Revita+™ Telehealth-Programms bekannt
Jun 26, 2023
Fractyl Health Reports Durable Improvement in Glucose Control, Weight Loss, and Insulin Reduction in T2D Patients Using Revita® in Open Label Phase of Revitalize 1 Pivotal Study at the American Diabetes Association 83rd Scientific Sessions
Jun 24, 2023
Fractyl Health Demonstrates Significant Improvement in Glucose Control and Obesity in Preclinical Studies of its Rejuva GLP-1 Based Pancreatic Gene Therapy (GLP1 PGTx) Compared to Chronic Semaglutide at ADA’s 83rd Scientific Sessions
Jun 13, 2023
Fractyl Health to Present Landmark Updates on Revita® and Rejuva® Programs at the 83rd American Diabetes Association
May 18, 2023
Fractyl Health Unveils Groundbreaking Pre-Clinical Proof of Concept Results for its Rejuva® Pancreatic Gene Therapy Platform for Metabolic Diseases at the American Society of Gene & Cell Therapy Congress
May 9, 2023
Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress
You are leaving Fractyl’s main website to go to Fractyl’s U.K. site.
By selecting Continue you will be directed to Fractyl’s U.K. site. If you would like to remain on Fractyl’s main site, select the Cancel button.
ContinueCancel
